Program
Etoricoxib
Also written as “etoricoxib”, “MK0663, etoricoxib” and “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days”.
Its studies are mostly in Osteoarthritis · Pain · Low Back Pain · Acute Pain · Dysmenorrhea, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organon | 230 open or running | phase 4since Aug 25, 2004 | Aug 25, 2004 | none ahead |
| Laboratorios Silanes S.A. de C.V. | 61 open or running | phase 3since Jul 13, 2021 | Jul 13, 2021 | Dec 31, 2026phase 3 · NCT06863701 |
| Analgesic Solutions | 10 open or running | phase 4since Dec 20, 2010 | Dec 20, 2010 | none ahead |
| Dexa Medica Group | 10 open or running | no phasesince Jan 30, 2018 | Jan 30, 2018 | none ahead |
| Laboratorios Liomont | 10 open or running | phase 3since Apr 15, 2026 | Apr 15, 2026 | none ahead |
| Pharmtechnology | 10 open or running | phase 1since Mar 31, 2021 | Mar 31, 2021 | none ahead |
| X-pert Med | 10 open or running | phase 1since Jan 5, 2011 | Jan 5, 2011 | none ahead |
Also a collaborator on its studies: epic-research-cro, pt-equilab-international and Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Aug 25, 2004.
- Dec 20, 2010Analgesic Solutions's first study: phase 4 study in Neuralgia, PostherpeticNew to Analgesic SolutionsAnalgesic Solutions · NCT01264237 · 120 enrolled · United Kingdom
- Jan 5, 2011X-pert Med's first study: phase 1 study in MyalgiaNew to X-pert MedX-pert Med · NCT01271348 · 50 enrolled · Germany
- Sep 2, 2011Phase 4 study in OsteoarthritisOrganon · NCT01429168
- Oct 27, 2011Phase 3 study in DysmenorrheaOrganon · NCT01462370 · 139 enrolled
- Mar 12, 2012Phase 3 study in Osteoarthritis, KneeOrganon · NCT01554163 · 239 enrolled
- Nov 5, 2013Phase 2 study in Osteoarthritis PainOrganon · NCT01980940 · 70 enrolled
- Jan 30, 2018Dexa Medica Group's first study: no phase study in HealthyNew to Dexa Medica GroupDexa Medica Group · NCT03422575 · 26 enrolled · Indonesia
- Mar 31, 2021Pharmtechnology's first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT04830579 · 34 enrolled · Russian Federation
- Jul 13, 2021Laboratorios Silanes S.A. de C.V.'s first study: phase 3 study in Back PainNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT04968158 · 124 enrolled · Mexico
- Sep 6, 2022Phase 1 study in PainLaboratorios Silanes S.A. de C.V. · NCT05533073 · 42 enrolled · Mexico
- Jul 18, 2024Phase 3 study in Acute PainLaboratorios Silanes S.A. de C.V. · NCT06517823 · 190 enrolled · Mexico
- Mar 3, 20252 phase 3 studiesLaboratorios Silanes S.A. de C.V. · NCT06863701, NCT06863662
- Dec 28, 2025Phase 3 study in BursitisLaboratorios Silanes S.A. de C.V. · NCT07328022 · 89 enrolled · Mexico
- Apr 15, 2026Laboratorios Liomont's first study: phase 3 study in AgnosiaNew to Laboratorios LiomontLaboratorios Liomont · NCT07549386 · 123 enrolled · Mexico
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Arthritis, GoutyLaboratorios Silanes S.A. de C.V. · NCT06863701
TargetBeta
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule
Other programs on PTGS2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| Celecoxibrule | Viatris | phase 4 | 78 |
| Meloxicamrule | Boehringer Ingelheim | phase 4 | 67 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07549386Agnosia · Mexico | 3 | Completed | Laboratorios Liomont | Mar 27, 2025 | 123 |
| NCT07328022Bursitis · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Aug 20, 2025 | 89 |
| NCT06863701Arthritis, Gouty · Mexico | 3 | Recruiting | Laboratorios Silanes S.A. de C.V. | Dec 31, 2026 | 72 |
| NCT06863662Spasm · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Sep 26, 2025 | 136 |
| NCT06517823Acute Pain · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Oct 4, 2024 | 190 |
| NCT05533073Pain · Mexico | 1 | Completed | Laboratorios Silanes S.A. de C.V. | Sep 7, 2020 | 42 |
| NCT04968158Back Pain · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Mar 15, 2022 | 124 |
| NCT04830579Bioequivalence · Russian Federation | 1 | UNKNOWN | Pharmtechnology | Apr 28, 2021 | 34 |
| NCT03422575Healthy · Indonesia | – | Completed | Dexa Medica Group | Dec 2015 | 26 |
| NCT01980940Osteoarthritis Pain | 2 | Completed | Organon | Nov 26, 2014 | 70 |
| NCT01554163Osteoarthritis, Knee | 3 | Completed | Organon | Mar 2013 | 239 |
| NCT01462370Dysmenorrhea | 3 | Completed | Organon | Jun 2012 | 139 |
| NCT01429168Osteoarthritis | 4 | Withdrawn | Organon | Aug 2012 | 0 |
| NCT01271348Myalgia · Germany | 1 | Completed | X-pert Med | Oct 2011 | 50 |
| NCT01264237Neuralgia, Postherpetic · United Kingdom | 4 | UNKNOWN | Analgesic Solutions | Aug 2011 | 120 |
| NCT01208207Spondylitis, Ankylosing | 3 | Completed | Organon | Nov 12, 2014 | 1,015 |
| NCT01208181Arthritis, Rheumatoid | 3 | Completed | Organon | Jun 9, 2014 | 1,404 |
| NCT00820027Pain, Postoperative | 3 | Completed | Organon | Dec 13, 2010 | 776 |
| NCT00788710Acute Pain Following a Total Abdominal Hysterectomy | 3 | Completed | Organon | Jul 2010 | 430 |
| NCT00757627Pain | 4 | Completed | Organon | Dec 2008 | 500 |
| NCT00694369Postoperative Dental Pain | 3 | Completed | Organon | Dec 2008 | 588 |
| NCT00393354Low Back Pain | 3 | Completed | Organon | Nov 2000 | 325 |
| NCT00393211Low Back Pain | 3 | Completed | Organon | Nov 2000 | 319 |
| NCT00380627Pain | 4 | Completed | Organon | Jan 31, 2006 | 337 |
| NCT00380523Pain | 4 | Completed | Organon | May 2005 | 237 |
| NCT00269191Osteoarthritis | 3 | Completed | Organon | Nov 7, 2003 | 528 |
| NCT00264147Arthritis, Rheumatoid | 2 | Completed | Organon | Mar 2008 | 761 |
| NCT00242489Osteoarthritis | 2 | Completed | Organon | Feb 1999 | 1,167 |
| NCT00095017Bone Neoplasms | 2 | Withdrawn | Organon | 0 | |
| NCT00092781Osteoarthritis | 3 | Completed | Organon | Feb 1, 2005 | 500 |
| NCT00092768Osteoarthritis | 3 | Completed | Organon | Feb 1, 2005 | 500 |
| NCT00092755Osteoarthritis | 3 | Completed | Organon | Nov 13, 2003 | 548 |
| NCT00092729Dysmenorrhea | 3 | Completed | Organon | Dec 6, 2002 | 129 |
| NCT00090181Chronic Low Back Pain | 4 | Completed | Organon | Mar 2005 | 401 |
How it is read
Names in the registry
- “etoricoxib”, 7 entries
- “Etoricoxib”, 4 entries
- “MK0663, etoricoxib”, 3 entries
- “MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days”, 2 entries
- “Etoricoxib 90 mg”, 2 entries
Codes read as this program: MK0663.
Conditions, from the studies’ own filings
- Osteoarthritis, 8 studies
- Pain, 5 studies
- Low Back Pain, 3 studies
- Acute Pain, 2 studies
- Dysmenorrhea, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.